AMCP 2024: Behind the research with YuQian Liu

Ahead of her session with Andy Killpack, Liu — senior director of specialty clinical solutions at Prime/MRx — shares current care management strategies for cell and gene therapy and the future of this exciting frontier

April 17, 2024

Alex Cook

Alex is a public relations manager for Prime Therapeutics. With more than 20 years of communications experience, Alex supports strategic communications for Clinical/Health Outcomes, Special Investigations/Fraud Waste Abuse, Government Affairs and more.

As more high-priced cell and gene therapies come onto the market, the health care industry is faced with a fundamental challenge: to make sure that patients can access these life-saving treatments.

That was the focus of the day two session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting, “Future of Cell and Gene Therapy Management: There is More Than Value Based Contracting!”

We caught up with one of the presenters, YuQian Liu, senior director of specialty clinical solutions at Prime Therapeutics/Magellan Rx, to talk about how managed care pharmacy professionals can rise to this challenge.

Stay tuned for additional coverage from AMCP Annual 2024 on our newsroom, and follow us on LinkedIn or X (formerly Twitter).

About Prime Therapeutics and Magellan Rx

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management LLC, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit primetherapeutics.com and magellanrx.com or follow us on X (Twitter) at @Prime_PBM and @Magellan_Rx.

AMCP 2024: Behind the research with YuQian Liu

Alex Cook

About Prime Therapeutics and Magellan Rx

Related news

April Fraud Focus – Protect yourself from health care fraud

Clinical News: April 2024

Drug Approvals Monthly Update: April 2024